Çocuk ve Ergenlerde Alkol Madde Kullanım Bozuklukları
Özet
Çocuk ve ergenlerde alkol ve madde kullanım bozuklukları, dünya genelinde ve Türkiye'de giderek artan ve kullanım yaşı düşen önemli bir halk sağlığı sorunudur. Ergenlik dönemi, fiziksel, bilişsel ve sosyal değişimlerin yaşandığı kritik bir evre olduğundan, bireyleri madde kullanımına ve buna bağlı olumsuz sonuçlara karşı oldukça yatkın hale getirmektedir. Etiyolojisinde genetik yatkınlıklar, prenatal maruziyet, DEHB ve depresyon gibi psikiyatrik sorunlar, akademik başarısızlık, aile içi ilgisizlik, şiddet ve özellikle madde kullanan bir arkadaş çevresine sahip olmak gibi bireysel, ailesel ve çevresel risk faktörleri önemli rol oynamaktadır. Tanı ve değerlendirme süreci; akademik başarıda düşüş ve davranış değişiklikleri gibi erken belirtilerin izlenmesini, aile ve okul gibi çoklu kaynaklardan detaylı öykü alınmasını ve öz bildirim ölçekleri ile biyolojik tarama testlerinin kullanılmasını içerir. Bağımlılık tedavisinde başarı oranını artırmak için erken müdahale kritik olup; nükslerin önlenmesi adına tedavi programları psikoeğitim, aile, grup veya bireysel terapileri (MET, BDT) kapsayacak şekilde çok boyutlu ve geniş kapsamlı olarak yapılandırılmalıdır. Ergenlerde psikofarmakolojik tedavi seçenekleri sınırlı olup, FDA tarafından sadece 16 yaş ve üzeri opioid kullanım bozuklukları için buprenorfin-nalokson kombinasyonuna onay verilmiştir.
Adolescent alcohol and substance use disorders represent a critical public health issue globally and in Turkey, characterized by increasing prevalence and declining onset ages. Since adolescence is a developmental phase involving rapid physical, cognitive, and social changes, it inherently elevates vulnerability to substance experimentation and long-term negative consequences. The etiology involves a complex interplay of genetic factors, prenatal exposure, psychiatric comorbidities like ADHD and depression, low academic achievement, parental neglect or domestic conflict, and particularly peer influence. Diagnosis and assessment rely on monitoring early behavioral cues, gathering multi-source histories from family and schools, and utilizing self-report scales alongside biological screenings. Given the chronic and relapsing nature of addiction, early intervention is pivotal, necessitating multi-dimensional treatment strategies that combine psychoeducation, individual or group therapies (such as CBT and MET), and family interventions to address psychosocial dynamics. Pharmacotherapy options for adolescents remain highly restricted; notably, the FDA has only approved the buprenorphine-naloxone combination for youth aged 16 and older with opioid use disorders, underscoring the urgent need for further clinical research in pediatric psychofarmacology.
Referanslar
Santrock, JW. Yaşam boyu gelişim (Çev.ed. Galip Yüksel). Ankara: Nobel Yayın. 2012.
Gray KM, Squeglia LM. Research Review: What have we learned about adolescent substance use?. Journal of Child Psychology and Psychiatry, 2018;59(6), 618-627. doi: 10.1111/jcpp.12783
Kring, AM, Davison GC, Neale JM, et al. Abnormal psychology. (10th ed.). New York: John Wiley & Sons, 2007.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Pub. 2013
Yule AM, Prince JB. Adolescent substance use disorders in the school setting. Child and Adolescent Psychiatric Clinics, 2012;21(1):175-186. doi: 10.1016/j.chc.2011.09.003
Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry, 2010;49(10):980-989. doi: 10.1016/j.jaac.2010.05.017
Swendsen J, Burstein M, Case B, et al. Use and abuse of alcohol and illicit drugs in US adolescents: Results of the National Comorbidity Survey–Adolescent Supplement. Archives of general psychiatry, 2012.69(4):390-398. doi: 10.1001/archgenpsychiatry.2011.1503
Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığını İzleme Merkezi 2019. Avrupa Uyuşturucu Raporu 2019: Eğilimler ve Gelişmeler. Lüksemburg: Avrupa Toplulukları Resmi Yayınlar Bürosu, 2019.
Bunnell RE, IT Agaku IT, Arrazola RA, et al. Intentions to smoke cigarettes among never-smoking US middle and high school electronic cigarette users: National Youth Tobacco Survey, 2011–2013. Nicotine & Tobacco Research, 2015;17(2):228-235. doi: 10.1093/ntr/ntu166
Majelantle RG, Bainame K, Masupu, K, et al. Youth Risk Behaviour Surveillance Survey Report 2010. Botswana Ministry of Education and Skills Development, 2011.
Johnston LD, Miech RA, O'Malley PM, et al. Monitoring the Future nationalsurvey results on druguse, 1975-2017: Overview, keyfindings on adolescent drug use. Institute for Social Research.2018.
Yüncü Z, Akyel B. Alkol ve Madde Bağımlılığı. Turkiye Klinikleri Child Psychiatry-Special Topics. 2018; 4(3):75-82
Öztekin C, Şengezer T, Özkara A. Effects of parental attitudes on the use of addictive substances in high school students. Nigerian Journal of Clinical Practice, 2017;20(9):1112-1121.
Ögel, K, Taner S, Eke CY. Onuncu sınıf öğrencileri arasında tütün, alkol ve madde kullanım yaygınlığı: İstanbul örneklemmi. Bağımlılık Dergisi, 2006;7(1):18-23.
Ulukoca N, Gökgöz Ş, Karakoç A. Kırklareli üniversitesi öğrencileri arasında sigara, alkol ve madde kullanım sıklığı. Fırat Tıp Dergisi, 2013;18(4):230-234.
Karatay G, Baş NG. Factors affecting substance use and self-efficacy status of students in eastern Turkey. Ciencia & saude coletiva, 2019;24:1317-1326. doi:10.1590/1413-81232018244.30252017
Bilaç Ö, Kavurma C, Önder A, et al. Bir bölge ruh sağlığı hastanesi çocuk ve ergen yataklı servisinde madde kullanımı nedeniyle yatarak tedavi gören gençlerin klinik ve sosyodemografik özellikleri. Klinik Psikiyatri Dergisi, 2019;22(4):463-471. doi: 10.5505/kpd.2019.30075
Karcı CK., Gürbüz AA, Özdemir FA, et al. Madde Kullanan Ergenlerde Psikiyatrik Eş Tanı, Bağımlılık Profili ve Tedavi İsteği: Çematem Verileri. Bağımlılık Dergisi, 2022;23(1):61-68.
Whitesell M, Bachand A, Peel, J, et al. Familial, social, and individual factors contributing to risk for adolescent substance use. Journal of addiction, 2013. doi: 10.1155/2013/579310
Sharp BM, Chen H. Neurogenetic determinants and mechanisms of addiction to nicotine and smoked tobacco. European journal of neuroscience, 2019;50(3):2164-2179.
Gelernter, J, Kranzler, HR. (2015). Genetics of addiction. Textbook of substance abuse treatment, 4.
Verhulst B, Neale MC, Kendler KS. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychological medicine, 2015;45(5):1061-1072. doi: 10.1017/S0033291714002165
Enoch MA. The role of early life stress as a predictor for alcohol and drug dependence. Psychopharmacology, 2011;214(1):17-31.
Lee SS, Humphreys KL, Flory K, et al. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clinical psychology review, 2011;31(3):328-341. doi: 10.1016/j.cpr.2011.01.006
Biederman, J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Journal of Clinical Psychiatry, 2003;64:3-8.
Burak M, Söyiler V, Pehlivan E. Adölesanlarda sigara içme ve madde kullanma prevalansı. Bağımlılık Dergisi, 2020;21(1):64-71.
Akkuş D, Karaca A, Şener DK, et al. Lise öğrencileri arasında madde kullanım sıklığı ve etkileyen faktörler. Bağımlılık Dergisi, 2016;17(4):139-151.
Ögel, K. Madde kullanım bozuklukları epidemiyolojisi. Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi Psikiyatri, 2005;1(47):61-64.
Townsend, L, Flisher AJ, King G. A systematic review of the relationship between high school dropout and substance use. Clinical child and family psychology review, 2007;10(4):295-317. doi: 10.1007/s10567-007-0023-7
Öztaş D, Kalyon A, Ertuğrul A, et al. Evaluation of risk factors affecting substance use among tenth-grade students. BioMed research international, 2018. doi: 10.1155/2018/1407649
D'amico EJ, Rodriguez A,Tucker JS, et al. Early and late adolescent factors that predict co-use of cannabis with alcohol and tobacco in young adulthood. Prevention Science, 2020;21(4):530-544. doi: 10.1007/s11121-020-01086-7
Bircan S, Erden G. Madde bağımlılığı: Aile ile ilgili olası risk faktörleri, algılanan ebeveyn kabul-reddi ve çocuk yetiştirme stilleri. Çocuk ve Gençlik Ruh Sağlığı Dergisi, 2011;18(3):211-222.
Skeer M, McCormick MC, SLT Normand SLT, et al. A prospective study of familial conflict, psychological stress, and the development of substance use disorders in adolescence. Drug Alcohol Depend, 2009;104(1-2):65-72. doi: 10.1016/j.drugalcdep.2009.03.017
Sorsdahl K, Stein DJ, Carrara H,. et al. Problem solving styles among people who use alcohol and other drugs in South Africa. Addictive behaviors, 2014;39(1):122-126. doi: 10.1016/j.addbeh.2013.09.011
Cservenka A. Neurobiological phenotypes associated with a family history of alcoholism. Drug and alcohol dependence, 2016;158:8-21. doi: 10.1016/j.drugalcdep.2015.10.021
Riva K, Allen-Taylor L, Schupmann WD et al. Prevalence and predictors of alcohol and drug use among secondary school students in Botswana: a cross-sectional study. BMC public health, 2018;18(1):1-14. doi: 10.1186/s12889-018-6263-2
Yalçın Ö, Çiftçi A. Alkol ve Madde Kullanim Bozuklukları. .Aynur Pekcanlar Akay (ed). Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları (s:470-526). Türkiye Çocuk ve Ergen Psikşyatrisi Dernegi, Ankara 2016
Şirin H, Uzun ME. Madde Kullanım Bozukluğu Tanısıyla ÇEMATEM’de Tedavi Gören Ergen Hastaların Sosyodemografik ve Klinik Özellikleri: Bursa Örneklemi. Turk J Child Adolesc Ment Health, 2021;28(2):151-158. doi: 10.4274/tjcamh.galenos.2021.46330
Tanidir C, Ciftci, AD, Doksat NG, et al. Trends and Gender Differences in Substance Use Among Children and Adolescents Admitted to an Addiction Treatment Center in Turkey: Years 2011–2013. Klinik Psikofarmakoloji Bülteni.2015;25(2):109-117. doi: 10.5455/bcp.20150210030606
Mason MJ, Aplasca A, Morales-Theodore R, et al. Psychiatric comorbidity and complications. Child and Adolescent Psychiatric Clinics, 2016;25(3):521-532. doi: 10.1016/j.chc.2016.02.007
Kaminer Y, Connor DF, Curry JF. Comorbid adolescent substance use and major depressive disorders: a review. Psychiatry, 2007;4(12):32–41.
Winningham RD, Banks DE, Buetlich MR, et al. Substance use disorder and posttraumatic stress disorder symptomology on behavioral outcomes among juvenile justice youth. The American journal on addictions, 2019;28(1):29-35. doi: 10.1111/ajad.12831
Peltzer, K. Early sexual debut and associated factors among in‐school adolescents in eight African countries. Acta Paediatrica, 2010;99(8):1242-1247. doi: 10.1111/j.1651-2227.2010.01874.x
Jacobus J, Squeglia LM, Infante MA, et al. Neuropsychological performance in adolescent marijuana users with co-occurring alcohol use: A three-year longitudinal study. Neuropsychology, 2015;29(6):829. doi: 10.1037/neu0000203
Nguyen-Louie TT, Castro N, Matt GE, et al. Effects of emerging alcohol and marijuana use behaviors on adolescents’ neuropsychological functioning over four years. Journal of studies on alcohol and drugs, 2015;6(5):738-748. doi: 10.15288/jsad.2015.76.738
Hanson KL, Cummins K, Tapert SF, et al. Changes in neuropsychological functioning over 10 years following adolescent substance abuse treatment. Psychology of Addictive Behaviors, 2011;25(1): 127. doi: 10.1037/a0022350
Hanson KL, Medina KL, Padula CB, et al. Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10-year outcomes. Journal of child & adolescent substance abuse, 2011;20(2):135-154. doi: 10.1080/1067828X.2011.555272
Meier MH, Caspi A, Ambler A. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences, 2012; 109(40):2657-2664. doi: 10.1073/pnas.1206820109
Jackson NJ, Isen JD, Khoddam R, et al. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proceedings of the National Academy of Sciences, 2016;113(5):500-508. doi: 10.1073/pnas.1516648113
Yüncü Z, Aydın C, Coşkunol H, et al., Çocuk ve ergenlere yönelik bir bağımlılık merkezine iki yıl süresince başvuran olguların sosyodemografik değerlendirilmesi. Bağımlılık Dergisi, 2006;7(1):31-37.
Bukstein OG. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. Journal of the American academy of child & adolescent psychiatry, 2005;44(6):609-621. doi: 10.1097/01.chi.0000159135.33706.37
Sapmaz ŞY, Sargın E, Ergin C, et al., DSM-5 düzey 2 madde kullanımı ölçeğinin türkçe formunun güvenirliği ve geçerliği. Bağımlılık Dergisi, 2016;17(3):116-122.
Ögel K, Aksoy A, Topuz A, et al. Ergenlerde uçucu madde kullanımı şiddetini değerlendirme ölçeğinin geliştirilmesi ve güvenilirlik çalışması. Türk Psikiyatri Dergisi, 2005;16(3):260-267.
Bozkurt M, Umut G, Evren C, et al. Clinical characteristics and laboratory test results of patients admitted to outpatient clinic for synthetic cannabinoid usage. Dusunen Adam The Journal of Psychiatry and Neurological Sciences, 2014;27(4):328. doi: 10.5350/DAJPN2014270407
Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and comorbid psychopathology. Child and Adolescent Psychiatric Clinics, 2010;19(3):609-623. doi: 10.1016/j.chc.2010.03.011
Balsa AI, Homer JF, French MT, et al. Substance use, education, employment, and criminal activity outcomes of adolescents in outpatient chemical dependency programs. The journal of behavioral health services & research, 2009;36(1):75-95.
Tanner-Smith EE, Wilson SJ, Lipsey MW. The comparative effectiveness of outpatient treatment for adolescent substance abuse: A meta-analysis. Journal of substance abuse treatment, 2013;44(2):145-158. doi: 10.1016/j.jsat.2012.05.006
Morral AR, McCaffrey DF, Ridgeway G. Effectiveness of Community-Based Treatment for Substance-Abusing Adolescents: 12-Month Outcomes of Youths Entering Phoenix Academy or Alternative Probation Dispositions. 2004; 18(3):257.
Hogue A, Henderson CE, Ozechowski TJ, et al., Evidence base on outpatient behavioral treatments for adolescent substance use: Updates and recommendations 2007–2013. Journal of Clinical Child & Adolescent Psychology, 2014;43(5): p. 695-720. doi: 10.1080/15374416.2014.915550
Hammond CJ, Sharma P. Medications for Substance Use and Relapse Prevention, in Treating Adolescent Substance Use, Springer. 2019:77-90. doi:10.1007/978-3-030-01893-1_7
Hammond CJ, Gray KM. Pharmacotherapy for substance use disorders in youths. Journal of child & adolescent substance abuse, 2016;25(4): 292-316. doi: 10.1080/1067828X.2015.1037517
Miranda R, Ray L, Blanchard A, et al., Effects of naltrexone on adolescent alcohol cue reactivity and sensitivity: an initial randomized trial. Addiction biology, 2014;19(5): 941-954. doi: 10.1111/adb.12050
Bagley SM, Levy S, Schoenberger SF. Alcohol use disorders in adolescents. Pediatric Clinics, 2019;66(6):1063-1074. doi: 10.1016/j.pcl.2019.08.003
Tomko RL, Jones JL, Gilmore AK, et al. N-acetylcysteine: a potential treatment for substance use disorders. Current psychiatry, 2018;17(6):30-36.
Dawes MA, Johnson BA, Ait-Daoud N, et al. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addictive behaviors, 2005;30(6): 1077-1085. doi: 10.1016/j.addbeh.2004.10.011
Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry, 2012;169(8):805-812. doi: 10.1176/appi.ajp.2012.12010055
Miranda R, Treloar H, Blanchard A, et al. Topiramate and motivational enhancement therapy for cannabis use among youth: A randomized placebo‐controlled pilot study. Addiction biology, 2017;22(3): 779-790. doi: 10.1111/adb.12350
Gray JC, Padovano HT, Wemm SE, et al. Predictors of topiramate tolerability in heavy cannabis using adolescents and young adults: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Journal of clinical psychopharmacology, 2018; 38(2):134. doi: 10.1097/JCP.0000000000000843
Borodovsky JT, Levy S, Fishman M, et al. Buprenorphine treatment for adolescents and young adults with opioid use disorders: a narrative review. Journal of addiction medicine, 2018. 12(3): p. 170. doi: 10.1097/ADM.0000000000000388
Fishman MJ, Winstanley EL, Curran E, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: Preliminary case‐series and feasibility. Addiction, 2010;105(9):1669-1676. doi: 10.1111/j.1360-0443.2010.03015.x
